Dr John Campbell is a new Prize Fellow in the Department of Health at the University of Bath.
Following a PhD in Immunology at the University of Birmingham, John undertook at 6-year Post-Doc at the University of Birmingham Medical School researching a type of blood cancer called Multiple Myeloma.
In his Post-Doc, John co-invented a series of assays for Multiple Myeloma, including Seralite - a quantitative multiplex lateral flow assay. Seralite is now on sale globally and the University spinout company (Serascience) recently completed a merger with Abingdon Health Ltd (York and Birmingham UK). John has experience of – and continues to be involved in – developing, validating and commercialising clinical assays.
The primary focus of John’s Prize Fellowship is to investigate how exercise and other lifestyle factors affect cancer risk as we grow older. John is a co-lead of a new Clinical Cancer Research Suite at the Royal United Hospital Bath and he is collaborating with national and international collaborators in this area.
Respond